Back pain is mainly caused due to muscular strains, strained ligaments, and muscular spasms in any region of the back. Chronic diseases such as herniated discs, arthritis, and osteoporosis can lead to back pain. Depending on the severity of the symptoms, back pain can be categorized- into acute and chronic back pain. Acute pain is most common type of back pain, which can be treated by medication.
Increasing prevalence of back pain among geriatric population is expected to boost growth of the global back pain therapy market
According to study published by Centre for Disea0se Control and Prevention (CDC) in 2012, around 20.3% of population was suffering from lower back pain in U.S. Moreover, according to study published by American Chronic Association in 2010, around 80% of population is projected to experience back pain once in a life. Therefore, increasing prevalence of back pain is expected to propel demand for back pain treatment, which in turn is expected to drive growth of global back pain therapy market over the forecast period. Furthermore, increasing ageing population is also expected to drive growth of the market, as chances of back pain increases with the age. According to study published by National Centre for Biotechnology Information (NCBI) in 2015, around 19.6% of individuals aged between 20 to 60 years were suffering from low back pain worldwide. According to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP) 2016, around 547 million people were above 60 years in Asia Pacific region and number is projected to reach around 1.3 billion by 2050. Increasing geriatric population in key regions such as North America, Europe, and Asia Pacific is expected to drive growth of the global back pain therapy market.
Back pain therapy market taxonomy -
Back pain therapy market is segmented on the basis of drug type, indication, distribution channel, and geography.
By Drug type-
By Distribution Channel-
North America is expected to hold a dominant position in global back pain therapy market, owing to development of new therapies
In 2017, U.S.-based Pfizer Inc. and Eli Lilly and company received the U.S. Food and Drug Administration (FDA) fast track designation for its drug tanezumab, which is indicated for the treatment of chronic low back pain. Tanezumab is a humanized monoclonal immunoglobulin G2 (IgG2), which could be used as an alternative to opioids. The development of such novel drugs in the U.S. is expected to drive growth of the market in North America. Asia Pacific is expected to be the second largest market for global back pain therapy market due to increasing prevalence of back pain in ageing population. According to a study published by United Nations Economic and Social Commission for Asia and the Pacific (ESCAP) in 2016, Asia Pacific region constitutes around 60% of the world’s geriatric population. According to study published by World Health Organization (WHO) in 2016, an estimated one out of six people in India are projected to suffer from arthritis once in life.
Key players operating in back pain therapy market include Celebrex, H.J. Harkins Company, Inc., Pfizer, Inc., Cipla Ltd., Apotex Inc., Jubilant Generics Ltd, Purdue Pharma L.P., Johnson & Johnson, Lupin Ltd., and Teva Pharmaceutical Industries Ltd.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.